Financial Performance - The company's operating revenue for Q1 2023 was ¥70,774,875.02, representing a year-on-year increase of 24.24%[5] - The net profit attributable to shareholders was -¥10,774,232.85, a decrease of 215.17% compared to the same period last year[5] - The basic earnings per share for the period was -¥0.05, reflecting a decline of 225.00% year-on-year[6] - Total operating revenue for Q1 2023 reached ¥70,774,875.02, a 24.3% increase from ¥56,966,471.66 in Q1 2022[18] - Net profit for Q1 2023 was a loss of ¥10,167,542.40, compared to a profit of ¥10,448,933.69 in Q1 2022, marking a significant decline[19] - Total comprehensive income for Q1 2023 was a loss of ¥10,167,542.40, contrasting with a comprehensive income of ¥10,448,933.69 in Q1 2022[20] Cash Flow and Liquidity - The cash flow from operating activities was -¥17,869,040.15, indicating a significant cash outflow[5] - Cash flow from operating activities showed a net outflow of ¥17,869,040.15 in Q1 2023, an improvement from a net outflow of ¥32,355,795.24 in Q1 2022[21] - Cash and cash equivalents at the end of Q1 2023 totaled ¥476,980,677.32, down from ¥644,093,513.66 at the end of Q1 2022[23] - The company reported a decrease in cash and cash equivalents by 45.89% due to operational expenditures during the reporting period[8] - Investment activities resulted in a net cash outflow of ¥386,659,252.68 in Q1 2023, compared to a net inflow of ¥325,070,667.89 in Q1 2022[23] - Financing activities generated a net cash outflow of ¥450,666.66 in Q1 2023, a decrease from a net inflow of ¥32,664,500.00 in Q1 2022[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,815,286,619.69, an increase of 11.34% from the end of the previous year[6] - As of March 31, 2023, the company's total assets amounted to RMB 1,815,286,619.69, an increase from RMB 1,630,417,953.78 at the end of 2022, reflecting a growth of approximately 11.3%[15][17] - The total current liabilities increased significantly to RMB 460,327,243.08 from RMB 263,110,017.18, marking an increase of approximately 75%[16][17] - The company’s total liabilities increased to RMB 467,274,148.14 from RMB 270,782,340.65, representing an increase of approximately 73%[17] - The company's long-term investments rose to RMB 21,815,727.11 from RMB 16,092,164.55, indicating a growth of around 35.2%[15][16] - The total equity attributable to shareholders decreased slightly to RMB 1,345,256,474.75 from RMB 1,355,986,306.78, a decrease of about 0.8%[17] Shareholder Information - The company had a total of 27,199 common shareholders at the end of the reporting period[11] - The largest shareholder, Mianyang Haoxiang Holdings Co., Ltd., holds 16.05% of the shares[11] Operational Costs and Expenses - The company experienced a 40.11% increase in main business costs due to higher revenue and a greater proportion of lower-margin products[8] - Total operating costs increased to ¥77,812,036.40 in Q1 2023, up 56.8% from ¥49,576,022.07 in Q1 2022[19] - Research and development expenses were ¥10,342,213.08 in Q1 2023, slightly up from ¥10,182,634.92 in Q1 2022[19] - The company is advancing the TOPCon battery project, which has led to a significant increase in management expenses[9] Inventory and Retained Earnings - The company’s inventory decreased to RMB 30,459,618.25 from RMB 32,447,645.65, a decline of about 6.1%[15][16] - The company’s retained earnings as of March 31, 2023, were RMB 301,640,838.13, down from RMB 312,415,070.98, a decrease of about 3.7%[17] - The company's cash and cash equivalents decreased to RMB 477,936,823.65 from RMB 883,344,513.14, representing a decline of about 46%[15][16] - The company reported a total of RMB 280,000,000.00 in trading financial assets as of March 31, 2023, compared to RMB 88,068,286.15 at the end of 2022, reflecting a significant increase of approximately 217%[15][16] Non-Current Assets - The company’s total non-current assets increased to RMB 755,847,363.35 from RMB 366,249,720.29, indicating a growth of approximately 106.5%[16][17]

调研单位名称 人员及职务 线上参与公司 2021 年度暨 2022 年第一季度网上业绩说明会 的投资者 公司董事长、董事会秘书（代行）翁康先生； 公司接待人员 及职务 公司总经理、财务总监（代管）陈剑嵩先生； 独立董事袁万凯先生。 调研主题 苏州麦迪斯顿医疗科技股份有限公司 2021 年度暨 2022 年第 一季度业绩说明会 证券代码：603990 证券简称：麦迪科技 编号：2022-001 苏州麦迪斯顿医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------|---------------------------------|--------------|-------| | 调研日期 | 2022 年 5 月 16 日 | 调研时间 | 14:00 | | | 调研地点 上交所上证路演中心 | | | | | □特定对象调研 | □分析师会议 | | | | □媒体采访 | ☑ 业绩说明会 | | | 调研形式 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | □其他（请文字说明其他活动内容） | | | | - ...

2022 年第三季度报告 证券代码：603990 证券简称：麦迪科技 苏州麦迪斯顿医疗科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 减变动幅度 | | 年初至报告期 末比上年同期 增减变动幅度 | | --- | --- | --- | --- | --- | | | | | 年初至报告期末 | | | | | (%) | | (%) | | 营业收入 | 62,890,700.25 | -5.68 | 205,800,162.98 | -5.65 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥142,909,462.73, a decrease of 5.63% compared to ¥151,431,740.16 in the same period last year[20]. - Net profit attributable to shareholders increased by 22.66% to ¥20,156,824.26 from ¥16,432,422.45 year-on-year, driven by higher gross margins from integrated solutions and medical services[21]. - The net cash flow from operating activities decreased by 157.44% to -¥3,180,972.08, primarily due to a reduction in tax refunds received[21]. - Basic earnings per share rose by 25.00% to ¥0.10 from ¥0.08 in the previous year[20]. - The weighted average return on equity increased by 0.39 percentage points to 1.82% from 1.43% year-on-year[20]. - The total assets at the end of the reporting period were ¥1,341,562,216.25, reflecting a 2.23% increase from ¥1,312,345,034.97 at the end of the previous year[20]. - The total profit reached CNY 27.28 million, an increase of 24.29% year-on-year, while the net profit attributable to shareholders was CNY 20.16 million, up 22.66% from the previous year[43]. - The company reported a total comprehensive income of 181,640,103.35, down from the previous period[148]. Strategic Direction - The company has a comprehensive strategy for expanding its smart hospital construction and high-quality development[13]. - The company is focused on integrating information technology with clinical knowledge to achieve intelligent medical decision support[31]. - The national health policy emphasizes the development of smart healthcare and remote medical services, which aligns with the company’s strategic direction[28]. - The company aims to enhance the informationization of nursing services by leveraging technologies such as cloud computing and big data[28]. - The company plans to implement a profit distribution plan for the next three years (2022-2024) as part of its shareholder return strategy[73]. - The company is focused on strategic expansion and investment opportunities to drive future growth[76]. - The company plans to enhance its capital structure by increasing retained earnings and optimizing equity distribution strategies[150]. Market Position and Competition - The company has established a leading market position in the clinical medical information system sector, with over 2,100 medical institutions across 32 provinces in China utilizing its products[37]. - The company has accumulated a strong customer base, including over 800 top-tier hospitals, enhancing its market reputation and demonstrating significant market penetration[37]. - The medical information technology sector is projected to reach ¥84.57 billion in IT spending by 2025, indicating significant market potential[26]. - The company is positioned in the medical information technology industry, which is supported by government policies aimed at enhancing healthcare services[27]. - The company emphasizes the importance of continuous product and technology development to maintain market competitiveness, given the rapid pace of software innovation[62]. Research and Development - R&D expenses increased by 68.16% to CNY 24.06 million, reflecting the company's commitment to technology and product innovation[48]. - The company focuses on both productization and customization in its R&D, enhancing the efficiency of tailored development to meet client needs[38]. - The company has a strong emphasis on technology and R&D, collaborating with research institutions to strengthen its capabilities in artificial intelligence and other advanced technologies[39]. - The intelligent early warning system for critical patients achieved a death risk prediction performance exceeding 80%, indicating significant application value in various medical fields[44]. Governance and Compliance - The company guarantees the authenticity, accuracy, and completeness of the semi-annual report[7]. - The company has committed to maintaining transparency and compliance with legal regulations in its governance practices[74]. - The company has confirmed the election of Chen Ning as a new board member, filling a vacancy left by a departing director[75]. - The company has established a commitment to minimize and standardize related party transactions, ensuring transparency and compliance with relevant regulations[92]. Financial Management - The company reported a cash balance of RMB 492,859,399.31 as of June 30, 2022, an increase from RMB 320,129,071.07 at the beginning of the period[118]. - The total current assets amounted to RMB 980,920,234.25, slightly up from RMB 964,894,750.65 at the beginning of the period[118]. - The company's long-term equity investments decreased to RMB 17,185,112.93 from RMB 27,278,699.83[118]. - The company reported accounts receivable of RMB 244,326,804.88, slightly down from RMB 250,383,730.14[118]. - The company has established high industry barriers due to the specialized knowledge required in medical information systems, making it challenging for new entrants[40]. Risks and Challenges - The company faced risks related to large accounts receivable and potential impacts from recurring COVID-19 outbreaks affecting hospital operations and project implementations[60]. - There is a risk of operational performance volatility due to various internal and external factors that cannot be predicted or controlled[63]. - The company must accurately grasp market trends to avoid risks associated with product development delays and misalignment with market demands[62]. Shareholder Matters - The company held three shareholder meetings during the reporting period, with all proposals approved and no rejected resolutions[74]. - The company has signed a share transfer agreement with An Investment Group, which will result in a change of control, with the new controlling shareholder expected to hold 9.09% of the total share capital post-issuance[66]. - The company plans to issue A-shares to Haoxiang Holdings, which will account for 9.09% of the total share capital after issuance[98]. - The total number of shares held by the top ten shareholders is 28,434,588, accounting for 13.26% of the total share capital[109].

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 41,953,365.73 for the year 2021, with the parent company reporting a net profit of RMB 48,484,542.20[6]. - In 2021, the company's operating revenue reached approximately CNY 353.85 million, an increase of 14.86% compared to CNY 308.08 million in 2020[24]. - The net profit attributable to shareholders was CNY 41.95 million, representing an 18.37% increase from CNY 35.44 million in 2020[24]. - The total profit for the year was RMB 51.34 million, an increase of 5.69% compared to the previous year[32]. - The net profit after deducting non-recurring gains and losses increased by 28.08% to CNY 33.06 million from CNY 25.81 million in 2020[24]. - The company's cash flow from operating activities decreased by 64.13% to CNY 36.04 million, down from CNY 100.48 million in 2020[26]. - The weighted average return on net assets decreased by 1.83 percentage points to 3.83% from 5.66% in 2020[24]. - The company's total assets decreased by 13.76% to CNY 1.31 billion from CNY 1.52 billion in 2020[24]. - The company’s net assets attributable to shareholders decreased by 10.74% to CNY 1.09 billion from CNY 1.23 billion in 2020[24]. Profit Distribution and Capital Plans - The company plans to distribute no profits for 2021, with a cash dividend ratio calculated at 168.50% based on a total repurchase expenditure of RMB 70,691,870.22[6]. - The proposed capital reserve conversion plan suggests a distribution of 3 additional shares for every 10 shares held, potentially increasing the total share capital to 214,401,344 shares[7]. - The board of directors has approved the profit distribution and capital reserve conversion plan, pending shareholder meeting approval[7]. Market Expansion and Development - The company reported a significant increase in market expansion efforts, particularly in hospital information technology, due to government investments[25]. - The company plans to continue developing new medical divisions and enhancing its service offerings in response to market demands[26]. - The company aims to enhance its CIS business by developing three major segments: "Operating Room," "ICU," and "Emergency Rescue," focusing on product advantages and market barriers[112]. - The company is actively expanding its market presence through the acquisition of Mary Hospital, which is expected to strengthen its operational capabilities[95]. Research and Development - The company has filed for and obtained 11 patents during the reporting period, including 7 invention patents[35]. - The company is developing an AI-based cardiovascular patient management platform, with an investment of RMB 674.21 million[83]. - Total R&D expenses amounted to RMB 71,265,936.52, representing 20.14% of total revenue[80]. - The company increased its R&D investment by 11.56% compared to the previous year, with expenses reaching RMB 48,004,978.09[79]. - The number of R&D personnel is 281, accounting for 39.25% of the total workforce[81]. Operational Challenges and Risks - The company has outlined potential risks in its operations, which are detailed in the management discussion section of the report[9]. - The company emphasizes the importance of investment risk awareness due to uncertainties in future plans and projections[8]. - The company faces risks related to the COVID-19 pandemic, which could delay project implementations and affect revenue recognition[116]. - Seasonal fluctuations in business operations are expected, with project completion and payment concentrated in the second half of the year, potentially leading to lower net profits in the first two quarters[117]. Governance and Compliance - The company has established a robust internal control system and revised various management regulations to enhance risk management capabilities[123]. - The audit report issued by Zhonghui Certified Public Accountants confirms the accuracy and completeness of the financial statements[5]. - The company has not reported any significant deficiencies in internal control during the reporting period[159]. - The company has disclosed 4 regular reports and 115 temporary announcements during the reporting period, ensuring transparent communication with investors[123]. Employee and Management Structure - The company reported a total of 716 employees, with 414 in the parent company and 302 in major subsidiaries[147]. - The employee composition includes 281 technical staff, 182 production personnel, and 96 sales personnel[147]. - The management team has extensive experience in various sectors, including finance and healthcare, which supports strategic decision-making[133]. - The company emphasizes talent development and offers targeted training programs for employees[150]. Environmental and Social Responsibility - The company does not belong to the key pollutant discharge units and actively fulfills its environmental responsibilities, adhering to all environmental policies[162]. - The company promotes energy conservation and resource efficiency through initiatives like double-sided printing and electronic documentation, contributing to environmental protection[164]. - The company emphasizes social responsibility by enhancing employee welfare and ensuring health and safety during the pandemic[166]. Financial Management and Investments - The company has made significant investments in R&D, focusing on AI-driven medical solutions, which are expected to drive future growth[91]. - The company has established partnerships with local health authorities, such as the Suzhou Health Commission, to enhance its software solutions in the healthcare sector[89]. - The company has initiated an employee stock ownership plan[138]. - The company plans to invest in establishing the招商麦迪医疗基金[139].

2022 年第一季度报告 证券代码：603990 证券简称：麦迪科技 苏州麦迪斯顿医疗科技股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增减变动 | | | --- | --- | --- | --- | | | | 幅度(%) | | | 营业收入 | 56,966,471.66 | | 20.97 | | 归属于上市公司股东的净利润 | 9,355,000.81 | | 39.31 | | 归属于上市公司股东的扣除非经常 | 8,821,487.2 ...

2021 年第三季度报告 证券代码：603990 证券简称：麦迪科技 苏州麦迪斯顿医疗科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 | | 年初至报告 | | --- | --- | --- | --- | --- | | | | 上年同期增 | 年初至报告期末 | 期末比上年 | | | | 减变动幅度 | | 同期增减变 | | | | (%) | | 动幅度(%) | | 营业收入 | 66,681,426.07 | -17.24 | 218,113,166.23 | 28.57 | | 归属于上市公司股东的净利润 | -2,195,765.61 | -123.17 | 14,236,656.84 | 705.40 | | 归属于上市公司股东的扣除非 | -5,384,777.60 | -159.88 | 8,995, ...

Financial Performance - The company reported a total revenue of 100 million RMB for the first half of 2021, representing a 20% increase compared to the same period last year[19]. - The net profit for the first half of 2021 was 15 million RMB, which is a 10% increase year-over-year[19]. - The company's operating revenue for the first half of 2021 was ¥151,431,740.16, representing a 70.01% increase compared to the same period last year[21]. - Net profit attributable to shareholders was ¥16,432,422.45, a significant increase from a net loss of ¥7,708,706.95 in the previous year[21]. - The net cash flow from operating activities increased by 46.51% to ¥5,538,355.44, primarily due to the rise in operating revenue[22]. - Basic earnings per share improved to ¥0.10 from a loss of ¥0.07 in the same period last year[22]. - The total profit reached 21.95 million yuan, marking a turnaround from loss to profit compared to the previous year[42]. - The company reported a net loss of ¥10,766,328.17 during the reporting period, impacting overall profitability[130]. Acquisitions and Investments - The company completed the acquisition of the remaining 49% stake in Haikou Mary Hospital, enhancing its position in the healthcare sector[28]. - The company completed the acquisition of 100% equity in Haikou Mary Hospital Co., Ltd. on February 4, 2021, following board and shareholder approvals[50]. - The company signed an equity acquisition intention agreement with Beijing Guowei Dahui Medical Industry Fund on June 18, 2020, intending to purchase at least 20% equity in Guowei Reproductive Hospital[84]. - The non-public offering of 19,863,488 shares was approved by the China Securities Regulatory Commission on September 10, 2020, and the shares were listed for trading on June 4, 2021[91]. Market and Industry Focus - The company is focusing on expanding its market presence and enhancing its product offerings in the healthcare technology sector[19]. - The medical software industry is supported by national policies, with increasing emphasis on public health services due to the aging population and pandemic response[29]. - The assisted reproductive industry is expected to grow significantly due to declining birth rates and the implementation of the "three-child" policy[30]. - The company aims to leverage its brand and market position to expand through mergers and acquisitions in the highly regulated assisted reproductive market[31]. Research and Development - The company is actively pursuing new technology developments to enhance its service offerings in the medical field[19]. - The company has a mature R&D system certified by CMMI5, ensuring high standards in software development processes[39]. - The company emphasizes the importance of continuous R&D for new products and technology upgrades to maintain market competitiveness[63]. - Research and development expenses decreased by 33.79% to 14.31 million yuan, reflecting a shift in focus towards capitalizing on R&D costs[44]. Financial Health and Risks - The company has outlined potential risks in its report, which investors should be aware of[6]. - The company faces risks related to the large amount of accounts receivable, which could lead to increased bad debt provisions if major clients' financial conditions deteriorate[61]. - The ongoing pandemic has caused delays in project implementation and revenue recognition, significantly impacting the company's income[62]. - The company's revenue and net profit exhibit seasonal fluctuations, with contract signings and project payments concentrated in the second half of the year, particularly in Q4[62]. Transparency and Compliance - The company has not faced any issues with the authenticity and completeness of its financial disclosures[6]. - The company has a strong commitment to maintaining transparency and accuracy in its financial reporting[7]. - The company has established a profit distribution policy to protect the interests of minority investors, ensuring compliance with the relevant regulations[81]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 35,519[94]. - The total number of shares held by the top ten shareholders is 56,568,000, accounting for 34.36% of the total shares[96]. - The company has committed to not exceeding 25% of its total shareholding for stock transfers during the tenure of its directors and senior management[78]. - The company ensures that any stock reduction after the lock-up period will not be below the initial public offering price[78]. Environmental Compliance - The company is not classified as a key pollutant discharge unit and actively complies with environmental protection policies[73]. - The company operates primarily in the software and information technology services industry, with no involvement in environmental pollution matters[74]. - The company has not taken measures to reduce carbon emissions during the reporting period[76]. Accounting and Financial Reporting - The financial statements are prepared in accordance with the relevant accounting standards, reflecting the company's financial position and operating results accurately[153]. - The company follows specific accounting policies for revenue recognition and asset depreciation based on its operational characteristics[152]. - The company’s accounting records are maintained in Renminbi (RMB)[156]. - The company has established a comprehensive framework for accounting treatment of business combinations, ensuring compliance with accounting standards[157].

Financial Performance - In 2020, the company's operating revenue was CNY 308,078,554.18, a decrease of 7.52% compared to CNY 333,116,193.35 in 2019[23]. - The net profit attributable to shareholders decreased by 24.41% to CNY 35,442,722.71 from CNY 46,887,055.64 in 2019[23]. - The net profit after deducting non-recurring gains and losses fell by 33.80% to CNY 25,812,050.75 compared to CNY 38,990,774.63 in 2019[23]. - The net cash flow from operating activities increased by 355.88% to CNY 100,479,244.99 from CNY 22,040,765.54 in 2019[23]. - The company's total assets increased by 100.15% to CNY 1,521,658,330.85 from CNY 760,265,101.93 in 2019[24]. - The net assets attributable to shareholders rose by 145.91% to CNY 1,226,498,334.77 from CNY 498,765,110.77 in 2019[24]. - Basic earnings per share decreased by 25.00% to CNY 0.24 from CNY 0.32 in 2019[25]. - The weighted average return on equity decreased by 4.02 percentage points to 5.66% from 9.68% in 2019[25]. - The company attributed the decline in net profit to a revenue drop of CNY 25,037,600 due to the pandemic, while fixed costs remained[26]. - The company reported a significant increase in revenue from the Mary Hospital, achieving 3,843.08 million RMB in operating income and a net profit of 1,341.43 million RMB for the year 2020[36]. Cash Dividend and Share Capital - The company plans to distribute a cash dividend of 0.66 CNY per 10 shares, totaling 10,766,328.41 CNY, which represents 30.38% of the net profit attributable to the parent company for 2020[5]. - The total share capital as of December 31, 2020, is 165,463,488 shares, after deducting 2,337,300 shares held in the repurchase account, the base for dividend distribution is 163,126,188 shares[5]. - In 2020, the net profit attributable to ordinary shareholders for 2020 was 35,443,025.23 CNY, with a profit distribution rate of 30.38%[119]. - In 2019, the cash dividend was 1.27 CNY per 10 shares, with a total of 14,281,756.55 CNY distributed, and a profit distribution rate of 30.46%[119]. - In 2018, the cash dividend was 2.10 CNY per 10 shares, totaling 16,933,314.30 CNY, with a profit distribution rate of 30.52%[121]. Audit and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[4]. - The board of directors and supervisory board confirm the authenticity, accuracy, and completeness of the annual report[7]. - The company has not violated decision-making procedures for external guarantees[7]. - There are no non-operating fund occupations by controlling shareholders or related parties[7]. - The company has established a plan to notify and disclose any share reduction intentions by major shareholders in advance[123]. - The company has a commitment to long-term shareholding, limiting annual share reductions to 25% of their total holdings[123]. Risks and Challenges - The company has detailed the main risks related to its operations in the report, including future development risks and countermeasures[8]. - The company emphasizes that forward-looking statements in the report involve uncertainties and do not constitute substantive commitments to investors[6]. - The company faces risks related to seasonal fluctuations in business operations, with revenue and net profit concentrated in the second half of the year, particularly in Q4[111]. - The company emphasizes the importance of continuous R&D for new products and technology upgrades to maintain market competitiveness, given the rapid evolution of software products[112]. Research and Development - The company’s total number of R&D personnel is 225, which constitutes 37.31% of the company's total workforce[73]. - Research and development expenses amounted to 43,032,347.82 CNY, representing 15.96% of total revenue[73]. - The company obtained 5 patents during the reporting period, including 3 invention patents and 2 utility model patents, enhancing its intellectual property portfolio[77]. - The company is focused on developing innovative solutions to improve the quality of care and patient outcomes in critical care settings[76]. Market Position and Strategy - The company has established a leading market position with its DoCare series clinical management information systems, which are applied in over 1,900 medical institutions across 32 provinces[46]. - The company aims to enhance its CIS business by developing three key areas: operating rooms, ICUs, and emergency rescue services, focusing on mobile, cloud, intelligent, and platform-based solutions[106]. - The company plans to actively seek acquisitions of qualified tertiary specialized hospitals or partnerships with qualified medical institutions to capture market share in the assisted reproductive medicine sector[99]. - The company is committed to improving medical quality management standards in its reproductive medicine services to mitigate clinical risks[113]. Financial Management - The company reported a significant increase in contract liabilities to ¥52,071,516.50, reflecting uncompleted contract work[87]. - The company’s cash dividend distribution plan proposes a payout of 0.66 yuan per 10 shares, totaling approximately 10.77 million yuan, which represents 30.38% of the net profit attributable to the parent company for 2020[118]. - The company is actively monitoring the performance of its financial products and adjusting strategies based on market conditions[149]. - The company has a financial management product linked to the London Interbank Offered Rate (LIBOR), with a potential yield of 1.40% per year if LIBOR exceeds 5%[151]. Subsidiaries and Acquisitions - The company completed the acquisition of 100% equity in Haikou Mary Hospital, with the relevant business license issued on March 23, 2021[140]. - The controlling subsidiary Haikou Mary Hospital Co., Ltd. has total assets of 37.63 million RMB and a net profit of 13.41 million RMB[97]. - The company signed a share acquisition intention agreement with the controlling shareholder of Beijing Guowei Health Reproductive Health Hospital, with due diligence completed[138]. Environmental Responsibility - The company actively fulfills its environmental responsibilities and complies with environmental policies, as it is not classified as a key pollutant discharge unit[157]. - The company has not disclosed environmental information for non-key pollutant discharge units due to the nature of its business, which primarily involves software development and does not contribute to environmental pollution[158].

Financial Performance - Operating revenue increased by 187.40% to CNY 47,093,244.80 compared to the same period last year[5] - Net profit attributable to shareholders was CNY 4,890,918.03, a significant recovery from a loss of CNY 17,397,120.67 in the previous year[5] - The company reported a basic earnings per share of CNY 0.04, recovering from a loss of CNY 0.11 per share in the previous year[7] - Revenue increased by CNY 30.71 million, a growth of 187.4%, mainly due to the recovery of operations to pre-pandemic levels and the consolidation of Haikou Mary Hospital's income[14] - Net profit for Q1 2021 was ¥7,929,049.10, compared to a net loss of ¥16,477,975.40 in Q1 2020, marking a turnaround in profitability[26] - The company's revenue for Q1 2021 reached ¥34,489,405.13, a significant increase of 196.5% compared to ¥11,608,748.61 in Q1 2020[28] Cash Flow - Cash flow from operating activities improved to a net outflow of CNY 13,196,761.79, compared to a larger outflow of CNY 19,172,443.55 in the same period last year[5] - Net cash flow from operating activities increased by CNY 5.98 million, driven by an increase of CNY 33.72 million in cash received from sales of goods and services compared to the same period last year[14] - Operating cash flow for Q1 2021 was negative at -¥13,196,761.79, an improvement from -¥19,172,443.55 in Q1 2020[31] - The cash inflow from operating activities was CNY 77,397,935.06, a 51.7% increase from CNY 51,005,829.75 in Q1 2020[34] - The net cash flow from operating activities was -CNY 1,797,672.97, an improvement from -CNY 6,856,776.43 in the same period last year[34] Assets and Liabilities - Total assets decreased by 10.55% to CNY 1,361,155,806.74 compared to the end of the previous year[5] - The company's total assets as of March 31, 2021, were ¥1,486,403,255.93, a decrease of 2.9% from ¥1,531,066,571.79 at the end of 2020[23] - Current assets totaled ¥1,062,725,146.95, down 13.1% from ¥1,222,338,242.75 at the end of 2020[23] - The total liabilities increased to ¥317,964,061.54, up from ¥303,058,756.33, reflecting a rise of 4.0%[23] - The company's equity decreased to ¥1,168,439,194.39 from ¥1,228,007,815.46, a decline of 4.9%[24] Investments and Acquisitions - The company acquired a 49% stake in Haikou Mary Hospital, impacting minority interests which decreased by 93.94%[13] - Investment activities generated a net cash outflow of CNY 433.09 million, mainly due to increased purchases of financial products and the acquisition of 49% equity in Haikou Mary Hospital[15] - The total investment cash outflow for Q1 2021 was ¥434,920,123.60, significantly higher than ¥46,862,939.59 in Q1 2020, reflecting aggressive investment strategies[32] Operating Costs and Expenses - Operating costs increased by CNY 6.35 million, a growth of 116.4%, primarily due to the increase in operating revenue[14] - Operating costs for Q1 2021 were ¥47,941,049.55, up from ¥39,960,895.44 in the same period last year, reflecting a year-over-year increase of 19.6%[24] - The company reported a total operating expenses of ¥30,294,431.28 in Q1 2021, up from ¥20,121,721.71 in Q1 2020, reflecting increased sales and management costs[28] Research and Development - Development expenses rose by 87.18% to CNY 1,146,780.00, mainly due to capitalized R&D costs for a new project[13] - Research and development expenses decreased by CNY 4.75 million, a reduction of 44.27%, due to the capitalization of R&D expenses related to a specific project[14] - Research and development expenses for Q1 2021 were ¥5,984,203.57, down 44.5% from ¥10,738,588.35 in Q1 2020[24] - Research and development expenses decreased to ¥1,730,670.40 in Q1 2021 from ¥8,189,283.64 in Q1 2020, indicating a strategic shift in resource allocation[28] Shareholder Information - The number of shareholders reached 12,006, indicating a stable shareholder base[9]